Lymphocyte-to-C-reactive protein ratio may serve as an effective biomarker to determine COVID-19 disease severity

Basit Öğe Kaydı
dc.contributor.authorBal, Tayibe
dc.contributor.authorDogan, Serdar
dc.contributor.authorCabalak, Mehmet
dc.contributor.authorDirican, Emre
dc.date.accessioned2024-09-18T20:13:27Z
dc.date.available2024-09-18T20:13:27Z
dc.date.issued2021
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractObjectives: We aimed to evaluate the ability of lymphocyte-C-reactive protein ratio (LCR) to discriminate between different levels of severity of COVID-19 disease. Methods: This retrospective observational single-center study was performed on 61 confirmed (PCR positive) COVID-19 patients between March and June 2020. The study population was separated into three groups: mild/moderate (n=24), severe (n=25) and critically ill (n=12). The optimal cutoff values of the LCR and neutrophil-to-lymphocyte ratio (NLR) in discriminating between patients with different severity levels were calculated by applying the receiver operating curve (ROC) analysis. Results: At baseline, the LCR decreased significantly across the three severity groups (mild/moderate > severe > critically ill). ROC analysis showed that a mean LCR of 43.21 was the cut-off value which best discriminated patients with the critically ill disease from severe patients (sensitivity: 84% and specificity: 69%). The discriminative performance of LCR (ROC AUC 0.820) was better than that of NLR (0.751) in this regard. LCR, unlike NLR was able to distinguish severe patients from mild/moderate patients, with a cut off value of 458.19 (sensitivity: 80% and specificity: 45%). Conclusion: LCR was observed to be able to distinguish COVID-19 infected patients of different severity (mild/moderate, severe and critically ill) and was superior to NLR in this regard.en_US
dc.identifier.doi10.1515/tjb-2020-0410
dc.identifier.endpage26en_US
dc.identifier.issn0250-4685
dc.identifier.issn1303-829X
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85103446503en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage21en_US
dc.identifier.trdizinid492701en_US
dc.identifier.urihttps://doi.org/10.1515/tjb-2020-0410
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/492701
dc.identifier.urihttps://hdl.handle.net/20.500.12483/9197
dc.identifier.volume46en_US
dc.identifier.wosWOS:000625120300004en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.publisherWalter De Gruyter Gmbhen_US
dc.relation.ispartofTurkish Journal of Biochemistry-Turk Biyokimya Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCOVID-19en_US
dc.subjectlymphocyte-C-reactive protein ratioen_US
dc.subjectneutrophil-to-lymphocyte ratioen_US
dc.subjectSARS-CoV-2en_US
dc.subjectseverityen_US
dc.titleLymphocyte-to-C-reactive protein ratio may serve as an effective biomarker to determine COVID-19 disease severityen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Tam Metin / Full Text
Boyut:
483.83 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu